MEDICAL FACILITIES CORP (DR.CA) Fundamental Analysis & Valuation

TSX:DR • CA58457V5036

16.97 CAD
+0.03 (+0.18%)
Last: Mar 9, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This DR.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

Taking everything into account, DR scores 6 out of 10 in our fundamental rating. DR was compared to 13 industry peers in the Health Care Providers & Services industry. Both the health and profitability get an excellent rating, making DR a very profitable company, without any liquidiy or solvency issues. DR is valued quite cheap, but it does not seem to be growing. These ratings could make DR a good candidate for value investing.


Dividend Valuation Growth Profitability Health

8

1. DR.CA Profitability Analysis

1.1 Basic Checks

  • DR had positive earnings in the past year.
  • DR had a positive operating cash flow in the past year.
  • Of the past 5 years DR 4 years were profitable.
  • Each year in the past 5 years DR had a positive operating cash flow.
DR.CA Yearly Net Income VS EBIT VS OCF VS FCFDR.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M

1.2 Ratios

  • DR's Return On Assets of 30.18% is amongst the best of the industry. DR outperforms 92.31% of its industry peers.
  • DR has a better Return On Equity (94.43%) than 100.00% of its industry peers.
  • With an excellent Return On Invested Capital value of 15.42%, DR belongs to the best of the industry, outperforming 92.31% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for DR is significantly above the industry average of 7.68%.
Industry RankSector Rank
ROA 30.18%
ROE 94.43%
ROIC 15.42%
ROA(3y)8.42%
ROA(5y)6.13%
ROE(3y)25.39%
ROE(5y)18.93%
ROIC(3y)16.37%
ROIC(5y)14.6%
DR.CA Yearly ROA, ROE, ROICDR.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

1.3 Margins

  • The Profit Margin of DR (31.60%) is better than 92.31% of its industry peers.
  • In the last couple of years the Profit Margin of DR has grown nicely.
  • DR has a better Operating Margin (15.59%) than 100.00% of its industry peers.
  • DR's Operating Margin has been stable in the last couple of years.
  • DR has a better Gross Margin (63.75%) than 84.62% of its industry peers.
  • In the last couple of years the Gross Margin of DR has remained more or less at the same level.
Industry RankSector Rank
OM 15.59%
PM (TTM) 31.6%
GM 63.75%
OM growth 3Y-0.97%
OM growth 5Y-1.3%
PM growth 3Y78.64%
PM growth 5Y55.2%
GM growth 3Y-0.53%
GM growth 5Y-0.42%
DR.CA Yearly Profit, Operating, Gross MarginsDR.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. DR.CA Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), DR is creating value.
  • DR has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for DR has been reduced compared to 5 years ago.
  • Compared to 1 year ago, DR has an improved debt to assets ratio.
DR.CA Yearly Shares OutstandingDR.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
DR.CA Yearly Total Debt VS Total AssetsDR.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • Based on the Altman-Z score of 1.42, we must say that DR is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of DR (1.42) is better than 61.54% of its industry peers.
  • DR has a debt to FCF ratio of 2.05. This is a good value and a sign of high solvency as DR would need 2.05 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 2.05, DR belongs to the best of the industry, outperforming 92.31% of the companies in the same industry.
  • DR has a Debt/Equity ratio of 1.02. This is a high value indicating a heavy dependency on external financing.
  • DR's Debt to Equity ratio of 1.02 is in line compared to the rest of the industry. DR outperforms 53.85% of its industry peers.
  • Even though the debt/equity ratio score it not favorable for DR, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 1.02
Debt/FCF 2.05
Altman-Z 1.42
ROIC/WACC1.94
WACC7.96%
DR.CA Yearly LT Debt VS Equity VS FCFDR.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.3 Liquidity

  • DR has a Current Ratio of 1.79. This is a normal value and indicates that DR is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.79, DR belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • DR has a Quick Ratio of 1.67. This is a normal value and indicates that DR is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.67, DR belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.79
Quick Ratio 1.67
DR.CA Yearly Current Assets VS Current LiabilitesDR.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. DR.CA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 60.81% over the past year.
  • DR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -41.68%.
  • DR shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.59% yearly.
EPS 1Y (TTM)60.81%
EPS 3Y10.86%
EPS 5Y0%
EPS Q2Q%-23.33%
Revenue 1Y (TTM)-41.68%
Revenue growth 3Y-5.96%
Revenue growth 5Y-3.59%
Sales Q2Q%-20.29%

3.2 Future

  • Based on estimates for the next years, DR will show a small growth in Earnings Per Share. The EPS will grow by 6.63% on average per year.
  • DR is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -12.02% yearly.
EPS Next Y49.02%
EPS Next 2Y3.89%
EPS Next 3Y4.45%
EPS Next 5Y6.63%
Revenue Next Year-20.97%
Revenue Next 2Y-16.85%
Revenue Next 3Y-15.97%
Revenue Next 5Y-12.02%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
DR.CA Yearly Revenue VS EstimatesDR.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M 400M
DR.CA Yearly EPS VS EstimatesDR.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 1

More info and screens

Find the best growth stocksShow best growing peers

8

4. DR.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 10.54, the valuation of DR can be described as reasonable.
  • 84.62% of the companies in the same industry are more expensive than DR, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 26.46, DR is valued rather cheaply.
  • A Price/Forward Earnings ratio of 12.33 indicates a correct valuation of DR.
  • 84.62% of the companies in the same industry are more expensive than DR, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.65, DR is valued a bit cheaper.
Industry RankSector Rank
PE 10.54
Fwd PE 12.33
DR.CA Price Earnings VS Forward Price EarningsDR.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, DR is valued cheaper than 100.00% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, DR is valued cheaper than 92.31% of the companies in the same industry.
Industry RankSector Rank
P/FCF 4.54
EV/EBITDA 4.83
DR.CA Per share dataDR.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • DR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • DR has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)0.22
PEG (5Y)N/A
EPS Next 2Y3.89%
EPS Next 3Y4.45%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. DR.CA Dividend Analysis

5.1 Amount

  • DR has a Yearly Dividend Yield of 2.12%.
  • DR's Dividend Yield is a higher than the industry average which is at 1.37.
  • DR's Dividend Yield is comparable with the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 2.12%

5.2 History

  • The dividend of DR decreases each year by -19.91%.
  • DR has been paying a dividend for at least 10 years, so it has a reliable track record.
  • DR has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)-19.91%
Div Incr Years1
Div Non Decr Years4
DR.CA Yearly Dividends per shareDR.CA Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6 0.8 1

5.3 Sustainability

  • DR pays out 6.72% of its income as dividend. This is a sustainable payout ratio.
DP6.72%
EPS Next 2Y3.89%
EPS Next 3Y4.45%
DR.CA Yearly Income VS Free CF VS DividendDR.CA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M
DR.CA Dividend Payout.DR.CA Dividend Payout, showing the Payout Ratio.DR.CA Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

DR.CA Fundamentals: All Metrics, Ratios and Statistics

MEDICAL FACILITIES CORP

TSX:DR (3/9/2026, 7:00:00 PM)

16.97

+0.03 (+0.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-06
Earnings (Next)03-12
Inst Owners9.84%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap301.39M
Revenue(TTM)257.36M
Net Income(TTM)81.33M
Analysts42.22
Price Target16.58 (-2.3%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.12%
Yearly Dividend0.35
Dividend Growth(5Y)-19.91%
DP6.72%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.6%
Min EPS beat(2)-7.54%
Max EPS beat(2)6.33%
EPS beat(4)2
Avg EPS beat(4)3.38%
Min EPS beat(4)-24.98%
Max EPS beat(4)39.71%
EPS beat(8)3
Avg EPS beat(8)-25.78%
EPS beat(12)5
Avg EPS beat(12)32.86%
EPS beat(16)7
Avg EPS beat(16)-103.27%
Revenue beat(2)1
Avg Revenue beat(2)-1.3%
Min Revenue beat(2)-4.5%
Max Revenue beat(2)1.91%
Revenue beat(4)1
Avg Revenue beat(4)-6.39%
Min Revenue beat(4)-18.84%
Max Revenue beat(4)1.91%
Revenue beat(8)3
Avg Revenue beat(8)-3.49%
Revenue beat(12)4
Avg Revenue beat(12)-2.43%
Revenue beat(16)5
Avg Revenue beat(16)-2.23%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-5.41%
EPS NQ rev (3m)-5.41%
EPS NY rev (1m)19.3%
EPS NY rev (3m)11.02%
Revenue NQ rev (1m)-1.53%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)0.01%
Valuation
Industry RankSector Rank
PE 10.54
Fwd PE 12.33
P/S 0.86
P/FCF 4.54
P/OCF 4.18
P/B 2.58
P/tB N/A
EV/EBITDA 4.83
EPS(TTM)1.61
EY9.49%
EPS(NY)1.38
Fwd EY8.11%
FCF(TTM)3.73
FCFY22%
OCF(TTM)4.06
OCFY23.91%
SpS19.66
BVpS6.58
TBVpS-0.86
PEG (NY)0.22
PEG (5Y)N/A
Graham Number15.44
Profitability
Industry RankSector Rank
ROA 30.18%
ROE 94.43%
ROCE 18.66%
ROIC 15.42%
ROICexc 19.71%
ROICexgc 46.81%
OM 15.59%
PM (TTM) 31.6%
GM 63.75%
FCFM 18.99%
ROA(3y)8.42%
ROA(5y)6.13%
ROE(3y)25.39%
ROE(5y)18.93%
ROIC(3y)16.37%
ROIC(5y)14.6%
ROICexc(3y)21.7%
ROICexc(5y)18.79%
ROICexgc(3y)53.59%
ROICexgc(5y)43.79%
ROCE(3y)19.81%
ROCE(5y)17.76%
ROICexgc growth 3Y35.06%
ROICexgc growth 5Y23.36%
ROICexc growth 3Y18.42%
ROICexc growth 5Y13.1%
OM growth 3Y-0.97%
OM growth 5Y-1.3%
PM growth 3Y78.64%
PM growth 5Y55.2%
GM growth 3Y-0.53%
GM growth 5Y-0.42%
F-Score6
Asset Turnover0.95
Health
Industry RankSector Rank
Debt/Equity 1.02
Debt/FCF 2.05
Debt/EBITDA 1.54
Cap/Depr 25.03%
Cap/Sales 1.64%
Interest Coverage 7.65
Cash Conversion 93.1%
Profit Quality 60.09%
Current Ratio 1.79
Quick Ratio 1.67
Altman-Z 1.42
F-Score6
WACC7.96%
ROIC/WACC1.94
Cap/Depr(3y)47.79%
Cap/Depr(5y)40.36%
Cap/Sales(3y)2.81%
Cap/Sales(5y)2.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.81%
EPS 3Y10.86%
EPS 5Y0%
EPS Q2Q%-23.33%
EPS Next Y49.02%
EPS Next 2Y3.89%
EPS Next 3Y4.45%
EPS Next 5Y6.63%
Revenue 1Y (TTM)-41.68%
Revenue growth 3Y-5.96%
Revenue growth 5Y-3.59%
Sales Q2Q%-20.29%
Revenue Next Year-20.97%
Revenue Next 2Y-16.85%
Revenue Next 3Y-15.97%
Revenue Next 5Y-12.02%
EBIT growth 1Y-46.1%
EBIT growth 3Y-6.86%
EBIT growth 5Y-4.85%
EBIT Next Year1.57%
EBIT Next 3Y-5.51%
EBIT Next 5Y-5.14%
FCF growth 1Y-6.31%
FCF growth 3Y4.28%
FCF growth 5Y3.38%
OCF growth 1Y-24.65%
OCF growth 3Y3.26%
OCF growth 5Y1.55%

MEDICAL FACILITIES CORP / DR.CA FAQ

What is the fundamental rating for DR stock?

ChartMill assigns a fundamental rating of 6 / 10 to DR.CA.


Can you provide the valuation status for MEDICAL FACILITIES CORP?

ChartMill assigns a valuation rating of 8 / 10 to MEDICAL FACILITIES CORP (DR.CA). This can be considered as Undervalued.


Can you provide the profitability details for MEDICAL FACILITIES CORP?

MEDICAL FACILITIES CORP (DR.CA) has a profitability rating of 8 / 10.


What is the expected EPS growth for MEDICAL FACILITIES CORP (DR.CA) stock?

The Earnings per Share (EPS) of MEDICAL FACILITIES CORP (DR.CA) is expected to grow by 49.02% in the next year.


How sustainable is the dividend of MEDICAL FACILITIES CORP (DR.CA) stock?

The dividend rating of MEDICAL FACILITIES CORP (DR.CA) is 5 / 10 and the dividend payout ratio is 6.72%.